UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Haematologica (Roma), 2015-12, Vol.100 (12), p.1571-1578

2015

Volltextzugriff (PDF)

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

Clinical cancer research, 2016-01, Vol.22 (1), p.86-95

2016

Volltextzugriff (PDF)

Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation

Nature medicine, 2003-12, Vol.9 (12), p.1498-1505

2003

Volltextzugriff (PDF)

Hematologic, biochemical, and cardiopulmonary effects of l-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy

European journal of haematology, 2009-04, Vol.82 (4), p.315-321

2009

Volltextzugriff (PDF)

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

Clinical cancer research, 2016-04, Vol.22 (7), p.1572-1582

2016

Volltextzugriff (PDF)

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Leukemia, 2014-11, Vol.28 (11), p.2188-2196

2014

Volltextzugriff (PDF)

Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension

British journal of haematology, 2005-08, Vol.130 (3), p.445-453

2005

Volltextzugriff (PDF)

Levels of soluble endothelium‐derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality

British journal of haematology, 2005-09, Vol.130 (6), p.943-953

2005

Volltextzugriff (PDF)

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Blood, 2013-11, Vol.122 (21), p.4182-4182

2013

Volltextzugriff (PDF)

Severity of pulmonary hypertension during vaso‐occlusive pain crisis and exercise in patients with sickle cell disease

British journal of haematology, 2007-01, Vol.136 (2), p.319-325

2007

Volltextzugriff (PDF)

A Pilot Study Of Rituximab In Patients With Moderate Aplastic Anemia, Diamond-Blackfan Anemia and Pure Red Cell Aplasia

Blood, 2013-11, Vol.122 (21), p.2479-2479

2013

Volltextzugriff (PDF)

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Blood, 2013-11, Vol.122 (21), p.118-118

2013

Volltextzugriff (PDF)

Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib – findings from an investigator initiated phase 2 study

Clinical cancer research, 2015-12, Vol.22 (7), p.1572-1582

2015

Volltextzugriff (PDF)

Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p

Blood, 2013-11, Vol.122 (21), p.673-673

2013

Volltextzugriff (PDF)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review

Haematologica (Roma), 2006-08, Vol.91 (8), p.1076

2006

Volltextzugriff (PDF)

Phosphodiesterase Inhibition Increases Fetal Hemoglobin in Sickle Cell Disease; L-Arginine Supplementation Does Not

Blood, 2007-11, Vol.110 (11), p.3396-3396

2007

Volltextzugriff (PDF)

Early Predictors of Fetal Hemoglobin Response to Hydroxyurea in Sickle Cell Disease

Blood, 2005-11, Vol.106 (11), p.2344-2344

2005

Volltextzugriff (PDF)

Pulmonary vascular effects of red blood cells containing S-nitrosated hemoglobin

American journal of physiology. Heart and circulatory physiology, 2004-12, Vol.287 (6), p.H2561-H2568

2004

Volltextzugriff (PDF)

research paper: Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease

British journal of haematology, 2007-01, Vol.136 (2), p.319-325

2007

Volltextzugriff (PDF)

Acute on Chronic Pulmonary Hypertension in Patients with Sickle Cell Disease

Blood, 2004-11, Vol.104 (11), p.1669-1669

2004

Volltextzugriff (PDF)

Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy

Blood, 2004-11, Vol.104 (11), p.235-235

2004

Volltextzugriff (PDF)

Combination Erythropoietin-Hydroxyurea Therapy in Sickle Cell Disease: NIH experience and literature review

Haematologica (Roma), 2006-08, Vol.91 (8), p.1076-1083

2006

Volltextzugriff (PDF)

Pulmonary vascular effects of red blood cells containing S-nitrosated hemoglobin

American journal of physiology. Heart and circulatory physiology, 2004-12, Vol.56 (6), p.H2561-H2568

2004

Volltextzugriff (PDF)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease : experience from the Nation I Institutes of Health and a literature review

Haematologica (Roma), 2006, Vol.91 (8), p.1076-1083

2006

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation

Hematologic, biochemical, and cardiopulmonary effects of l-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension

Levels of soluble endothelium‐derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Severity of pulmonary hypertension during vaso‐occlusive pain crisis and exercise in patients with sickle cell disease

A Pilot Study Of Rituximab In Patients With Moderate Aplastic Anemia, Diamond-Blackfan Anemia and Pure Red Cell Aplasia

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib – findings from an investigator initiated phase 2 study

Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review

Phosphodiesterase Inhibition Increases Fetal Hemoglobin in Sickle Cell Disease; L-Arginine Supplementation Does Not

Early Predictors of Fetal Hemoglobin Response to Hydroxyurea in Sickle Cell Disease

Pulmonary vascular effects of red blood cells containing S-nitrosated hemoglobin

research paper: Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease

Acute on Chronic Pulmonary Hypertension in Patients with Sickle Cell Disease

Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy

Combination Erythropoietin-Hydroxyurea Therapy in Sickle Cell Disease: NIH experience and literature review

Pulmonary vascular effects of red blood cells containing S-nitrosated hemoglobin

Combination erythropoietin-hydroxyurea therapy in sickle cell disease : experience from the Nation I Institutes of Health and a literature review

Suchergebnisse filtern